MHRA launches new programme to tackle evidence gaps on women’s health
Women’s Health Programme aims to support innovation in women’s health and better understand how the risks and benefits of medicines and medical devices may differ for women

Women are set to benefit from better evidence on medicines and medical devices, including how their risks and benefits may differ for women, under a new programme launched today by the Medicines and Healthcare products Regulatory Agency (MHRA).
Despite making up 51% of the population, women continue to face gaps in research and treatment across a range of health conditions. They have historically been underrepresented in clinical research, limiting the evidence available on medicines and medical devices during pregnancy and across reproductive health. Unmet needs also remain for conditions specific to women, as well as those that present differently or disproportionately in women.
An MHRA analysis of all 4,616 UK clinical trial applications submitted between 2019 and 2023 highlighted continuing gaps in representation. Pregnant women were represented in just 1.1% of trials, while breastfeeding women were represented in 0.6%.
The Women’s Health Programme aims to address these challenges and explore how better data and scientific advancements can more accurately reflect women’s needs.
Women’s Health Minister, Baroness Gillian Merron, said:
“For too long, women’s health has been overlooked. Women make up more than half of our population, yet they have been underrepresented in the research that shapes the medicines and devices they rely on. That is not good enough, and we are determined to change it.
“This new programme is a welcome step. Together with our renewed Women’s Health Strategy, it will mean better evidence, better treatments, and a health system that listens to women and works for them.”
Lawrence Tallon, MHRA Chief Executive, said:
“Closing the gaps in our understanding of how the risks and benefits of medicines and medical devices differ for women is both a challenge and a huge opportunity.
“Better evidence can help us understand where important differences exist, support researchers and innovators and create opportunities for healthcare that is better tailored to women’s needs.”
Medicines and medical devices are complex, and factors such as biology, age, pregnancy and other health conditions can affect how people respond to them. The programme will bring together patients, researchers, healthcare professionals, and industry to strengthen the evidence available, while maintaining our robust standards of safety, quality and effectiveness.
Women’s health is also a major area for innovation. The UK’s rapidly growing FemTech sector already has an annual turnover of nearly £300 million, with technologies being developed across areas from reproductive health to long-term conditions and healthy ageing.
By working with researchers and innovators early and building better evidence about how the benefits and risks of medicines may differ for women, the MHRA wants to foster an environment where promising new products can be developed and reach patients earlier.
Naho Yamazaki, Deputy Director of Policy and Partnerships at the Health Research Authority, said:
“We welcome the MHRA’s Women’s Health Programme and its ambition to strengthen the evidence base for women’s health. Ensuring that people who are under-represented in research are considered and included in clinical trials is essential if research is to generate evidence that is relevant to the populations who will ultimately use new medicines and treatments.
“Our joint guidance with the MHRA on developing an Inclusion and Diversity Plan offers a practical framework to help researchers consider, from the earliest stages of study design, how their participant population can better reflect the people who may benefit from the research. This will help make sure that women, girls and those who are pregnant or breastfeeding are not left behind in research that is relevant to them.
“The guidance, and the MHRA’s Women’s Health Programme, will contribute to the important work being undertaken across the health and social care research sector to make studies more inclusive and representative, helping to ensure that the evidence generated better reflects diverse populations and supports efforts to reduce health inequalities.”
Michelle Riddalls OBE, CEO of PAGB, The Consumer Healthcare Association, said:
“It’s positive to see the MHRA’s new Women’s Health Programme points to a clear focus on closing longstanding evidence gaps while supporting responsible innovation.
“Better evidence can help women make more informed choices as well as creating opportunities to widen access to appropriate treatments through the reclassification of medicines, supporting more women to manage their health through self-care. We welcome the MHRA’s ambition to ensure that the regulatory system continues to evolve with new evidence and supports appropriate innovation that can make a real difference to women’s health.
“In recent times we have seen both low‑dose Estradiol vaginal products and Estriol cream reclassified which have transformed access to Hormone Replacement Therapy (HRT) for thousands of women, positive examples of providing women with greater choice and more convenient access to treatments”
The programme has been shaped by patients, including through the MHRA’s Patient and Public Community and a focus group delivered by the Patients Association. It is the first part of a wider MHRA initiative to address health inequalities as outlined in the recently launched 2030 Strategy.
The Women’s Health Programme is the MHRA’s regulatory contribution to the wider government ambition to improve women’s health through the renewed Women’s Health Strategy for England and corresponding work in Scotland, Wales and Northern Ireland.
The announcement will be made at the inaugural DIA-MHRA Global Summit, held in London on 16–17 November 2026 as part of London Life Sciences Week. Hosted jointly by the MHRA and the Drug Information Association (DIA), the Summit brings together international regulators, industry leaders, researchers, healthcare professionals and patient representatives to explore how global collaboration can support innovation and how this innovation can reach patients faster.
